Home  >  Research  >  Labs  >  Centres & Facilities  >  TRANSLATIONAL CANCER RESEARCH


de Rie D et aland FANTOM 5 Consortium (including LN Winteringham). An integrated expression atlas of miRNAs and their promoters in human and mouse. 2017 Nat Biotechnol. Sep;35(9):872-878.

Arner, E., Daub, C.O., Vitting-Seerup, K., and FANTOM 5 Consortium (including LN Winteringham) 2015, Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells, SCIENCE, 347, pp. 1010-1014.

Forrest, A.R.R., Kawaji, H., Rehli, M., and FANTOM 5 Consortium (including LN Winteringham) 2014, A promoter-level mammalian expression atlas, Nature, 507, 7493, pp. 462-470.

Andersson, R., Gebhard, C., Miguel-Escalada, I., and FANTOM 5 Consortium (including LN Winteringham)2014, An atlas of active enhancers across human cell types and tissues, NATURE, 507, pp. 455-467.

Endersby, R., Majewski, I.J., Winteringham, L., Beaumont, J.G., Samuels, A., Scaife, R., Lim, E., Crossley, M., Klinken, S.P., Lalonde, J.P.2008, Hls5 regulated erythroid differentiation by modulating GATA-1 activity,Blood, 111, pp. 1946-1950.

Winteringham, L.N., Endersby, R., Kobelke, S.J., McCulloch, R.K., Williams, J.H., Stillitano, J., Cornwall, S.M., Ingley, E., Klinken, S.P.2006, Myeloid Leukemia Factor 1 Associates with a Novel Heterogeneous Nuclear Ribonucleoprotein U-like Molecule, Journal of Biological Chemistry , 281, 50, pp. 38791-3800

Lim, R., Winteringham, L.N., Williams, J.H., McCulloch, R.K., Ingley, E., Tiao, J.Y-H., Lalonde, J-P., Tsai, S., Tilbrook, P.A., Sun, Y., Wu, X., Morris, S.W., Klinken, S.P.2002, MADM, a Novel Adaptor Protein That Mediates a Phosphorylation of the 14-3-3 Binding Site of Myeloid Leukemia Factor 1, Journal of Biological Chemistry, 277, 3, pp. 40997-41008

Williams, J.H., Daly, L.N., Ingley, E., Beaumont, J.G., Tilbrook, P.A., Lalonde, J.P., Stillitano, J.P., Klinken, S.P.1999, HLS7, a hemopoietic lineage switch gene homologous to the leukemia-inducing gene MLF1, EMBO Journal, 18, 20, pp. 5559-5

Chopra M, et al Enhanced Detection of Desmoplasia by Targeted Delivery of Iron Oxide Nanoparticles to the Tumour-Specific Extracellular Matrix. Pharmaceutics. 2021 Oct 12;13(10):1663.

Yeow YL, et al. ECM Depletion Is Required to Improve the Intratumoral Uptake of Iron Oxide Nanoparticles in Poorly Perfused Hepatocellular Carcinoma. Front Oncol. 2022 Feb 22;12:837234.